598.6K XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Edwin Rock | Chief Medical Officer | 20 Jun 2024 | 115,000 | 680,403 (1%) | 0% | 0.3 | 30,717 | Common Stock | |
| Edwin Rock | Chief Medical Officer | 20 Jun 2024 | 190,000 | 565,403 (1%) | 0% | 0.3 | 48,108 | Common Stock | |
| Brian M. Hahn | SVP Finance, CFO | 18 Jun 2024 | 17,500 | 70,643 (0%) | 0% | 0.2 | 4,335 | Common Stock | |
| Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Mark Alan Goldberg | Director | 01 May 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | ||
| Patricia S. Andrews | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Scott T. Jackson | Director | 01 May 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | ||
| Timothy R. Pearson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Scott Koenig | Director | 01 May 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | ||
| Rachel K. King | Director | 01 May 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | ||
| Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 3.00 per share. | 29 Mar 2024 | 5,209 | 98,459 (0%) | 0% | 3 | 15,627 | Common Stock |
| Mark Alan Goldberg | Director | 29 Mar 2024 | 4,584 | 24,828 (0%) | 0% | 3 | 13,752 | Common Stock | |
| Hahn M. Brian | SVP Finance, CFO | 12 Jan 2024 | 250,000 | 250,000 | - | - | Employee Stock Option (right to buy) | ||
| Rath Chinmaya | SVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 250,000 | 250,000 | - | - | Employee Stock Option (right to buy) | |
| Johnson S. Bruce | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 250,000 | 250,000 | - | - | Employee Stock Option (right to buy) | |
| Harout Semerjian | Director, Chief Executive Officer | 12 Jan 2024 | 695,000 | 695,000 | - | - | Employee Stock Option (right to buy) | ||
| Rock Edwin | Chief Medical Officer | 12 Jan 2024 | 250,000 | 250,000 | - | - | Employee Stock Option (right to buy) | ||
| King Rachel K. | Director | 29 Dec 2023 | 4,238 | 511,860 (1%) | 0% | 2.4 | 10,002 | Common stock | |
| Mark Alan Goldberg | Director | 29 Dec 2023 | 5,827 | 20,244 (0%) | 0% | 2.4 | 13,752 | Common stock | |
| Patricia Andrews S. | Director | Grant, award, or other acquisition of securities at price $ 2.36 per share. | 29 Dec 2023 | 5,191 | 58,608 (0%) | 0% | 2.4 | 12,251 | Common stock |
| Mark Alan Goldberg | Director | 30 Sep 2023 | 9,167 | 14,417 (0%) | 0% | 1.5 | 13,751 | Common stock | |
| Patricia S. Andrews | Director | Grant, award, or other acquisition of securities at price $ 1.50 per share. | 30 Sep 2023 | 8,167 | 53,417 (0%) | 0% | 1.5 | 12,251 | Common stock |
| Rachel K. King | Director | 30 Sep 2023 | 6,667 | 507,622 (1%) | 0% | 1.5 | 10,001 | Common stock | |
| Edwin Rock | Chief Medical Officer | 21 Sep 2023 | 30,403 | 375,403 (0%) | 0% | 1.4 | 41,956 | Common Stock | |
| Edwin Rock | Chief Medical Officer | 21 Sep 2023 | 35,000 | 345,000 (0%) | 0% | 1.4 | 48,300 | Common Stock | |
| Scott Koenig | Director | 01 Jun 2023 | 21,000 | 0 | - | - | Stock option (right to buy) | ||
| Scott Koenig | Director | 01 Jun 2023 | 21,000 | 36,750 (0%) | 0% | 0.6 | 12,600 | Common Stock | |
| Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Mark Alan Goldberg | Director | 19 May 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | ||
| Patricia S. Andrews | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Scott T. Jackson | Director | 19 May 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | ||
| Timothy R. Pearson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Scott Koenig | Director | 19 May 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | ||
| Rachel K. King | Director | 19 May 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | ||
| Brian M. Hahn | SVP Finance, CFO | 17 May 2023 | 3,700 | 53,143 (0%) | 0% | 2.0 | 7,215 | Common Stock | |
| Daniel M. Junius | Director | Purchase of securities on an exchange or from another person at price $ 1.56 per share. | 10 May 2023 | 30,000 | 93,250 (0%) | 0% | 1.6 | 46,800 | Common Stock |
| Bruce S. Johnson | SVP & Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 1.57 per share. | 08 May 2023 | 13,500 | 138,980 (0%) | 0% | 1.6 | 21,195 | Common Stock |
| Rachel K. King | Director | 29 Mar 2023 | 3,334 | 515,194 (1%) | 0% | 3 | 10,002 | Common Stock | |
| Scott Koenig | Director | 27 Jan 2023 | 10,500 | 0 | - | - | Stock Option (right to buy) | ||
| Scott Koenig | Director | 27 Jan 2023 | 10,500 | 15,750 (0%) | 0% | 2.6 | 26,775 | Common Stock | |
| Sandell D Scott | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 3.12 per share. | 25 Jan 2023 | 1,648,908 | 2,730,334 (6%) | 3% | 3.1 | 5,142,614 | Common Stock |
| Sandell D Scott | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 3.12 per share. | 25 Jan 2023 | 1,351,092 | 2,237,196 (5%) | 3% | 3.1 | 4,213,786 | Common Stock |
| Sandell D Scott | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 3.26 per share. | 25 Jan 2023 | 293,645 | 3,588,288 (8%) | 0% | 3.3 | 958,428 | Common Stock |
| Sandell D Scott | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 3.26 per share. | 25 Jan 2023 | 358,371 | 4,379,242 (10%) | 0% | 3.3 | 1,169,687 | Common Stock |
| Brian M. Hahn | SVP Finance, CFO | 19 Jan 2023 | 246,300 | 246,300 | - | - | Employee Stock Option (right to buy) | ||
| Harout Semerjian | Director, Chief Executive Officer | 19 Jan 2023 | 651,200 | 651,200 | - | - | Employee Stock Option (right to buy) | ||
| Edwin Rock | Chief Medical Officer | 19 Jan 2023 | 244,800 | 244,800 | - | - | Employee Stock Option (right to buy) | ||
| Sandell D Scott | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 2.76 per share. | 05 Jan 2023 | 39,223 | 4,737,613 (10%) | 0% | 2.8 | 108,201 | Common Stock |
| Sandell D Scott | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 2.76 per share. | 05 Jan 2023 | 32,139 | 3,881,933 (8%) | 0% | 2.8 | 88,659 | Common Stock |
| Rachel K. King | Director | 31 Dec 2022 | 7,500 | 7,500 (0%) | 0% | 0 | Common Stock | ||
| Rachel K. King | Director | 31 Dec 2022 | 11,641 | 500,955 (1%) | 0% | 0 | Common Stock | ||
| Sandell D Scott | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 2.99 per share. | 30 Dec 2022 | 96,084 | 4,832,890 (11%) | 0% | 3.0 | 287,301 | Common Stock |
| Sandell D Scott | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 3.02 per share. | 30 Dec 2022 | 66,690 | 4,928,974 (11%) | 0% | 3.0 | 201,404 | Common Stock |
| Sandell D Scott | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 3.02 per share. | 30 Dec 2022 | 54,645 | 4,038,732 (9%) | 0% | 3.0 | 165,028 | Common Stock |
| Sandell D Scott | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 30 Dec 2022 | 45,930 | 3,914,072 (8%) | 0% | 2.9 | 133,643 | Common Stock |
| Sandell D Scott | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 30 Dec 2022 | 56,054 | 4,776,836 (10%) | 0% | 2.9 | 163,100 | Common Stock |
| Sandell D Scott | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 2.99 per share. | 30 Dec 2022 | 78,730 | 3,960,002 (9%) | 0% | 3.0 | 235,411 | Common Stock |
| Edwin Rock | Chief Medical Officer | 22 Dec 2022 | 110,000 | 310,000 (0%) | 0% | 2.3 | 247,500 | Common Stock | |
| Daniel M. Junius | Director | Purchase of securities on an exchange or from another person at price $ 1.87 per share. | 17 Nov 2022 | 20,000 | 63,250 (0%) | 0% | 1.9 | 37,400 | Common Stock |
| Edwin Rock | Chief Medical Officer | 14 Nov 2022 | 100,000 | 100,000 (0%) | 0% | 1.4 | 143,000 | Common Stock | |
| Edwin Rock | Chief Medical Officer | 14 Nov 2022 | 100,000 | 200,000 (0%) | 0% | 1.7 | 166,000 | Common Stock | |
| Timothy R. Pearson | Director | Purchase of securities on an exchange or from another person at price $ 1.29 per share. | 11 Nov 2022 | 19,400 | 24,650 (0%) | 0% | 1.3 | 25,026 | Common Stock |
| John L. Magnani | SVP of Research, CSO | Purchase of securities on an exchange or from another person at price $ 1.17 per share. | 11 Nov 2022 | 45,045 | 366,078 (0%) | 0% | 1.2 | 52,703 | Common Stock |
| Brian M. Hahn | SVP Finance, CFO | 11 Nov 2022 | 20,000 | 56,843 (0%) | 0% | 1.1 | 21,200 | Common Stock | |
| Armand Girard | SVP, Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 1.05 per share. | 11 Nov 2022 | 6,500 | 29,161 (0%) | 0% | 1.1 | 6,825 | Common Stock |
| Harout Semerjian | Director, Chief Executive Officer | 11 Nov 2022 | 25,000 | 25,000 (0%) | 0% | 1.3 | 32,250 | Common Stock | |
| Edwin Rock | Chief Medical Officer | 02 Sep 2022 | 200,000 | 200,000 | - | - | Employee stock option (right to buy) | ||
| Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Mark Alan Goldberg | Director | 18 May 2022 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | ||
| Patricia S. Andrews | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Scott T. Jackson | Director | 18 May 2022 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | ||
| Timothy R. Pearson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Scott Koenig | Director | 18 May 2022 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | ||
| Rachel K. King | Director | 18 May 2022 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | ||
| John L. Magnani | SVP of Research, CSO | Sale of securities on an exchange or to another person at price $ 1.09 per share. | 09 Mar 2022 | 3,227 | 321,033 (0%) | 0% | 1.1 | 3,517 | Common Stock |
| Brian M. Hahn | SVP Finance, CFO | 09 Mar 2022 | 2,917 | 36,843 (0%) | 0% | 1.1 | 3,180 | Common Stock | |
| Armand Girard | SVP, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 1.09 per share. | 09 Mar 2022 | 2,339 | 22,661 (0%) | 0% | 1.1 | 2,550 | Common Stock |
| John L. Magnani | SVP of Research, CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| John L. Magnani | SVP of Research, CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 25,000 | 25,000 | - | - | Employee Stock Option (right to buy) | |
| Brian M. Hahn | SVP Finance, CFO | 21 Jan 2022 | 164,700 | 164,700 | - | - | Employee Stock Option (right to buy) | ||
| Brian M. Hahn | SVP Finance, CFO | 21 Jan 2022 | 47,700 | 47,700 | - | - | Employee Stock Option (right to buy) | ||
| Armand Girard | SVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 47,700 | 47,700 | - | - | Employee Stock Option (right to buy) | |
| Armand Girard | SVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 144,700 | 144,700 | - | - | Employee Stock Option (right to buy) | |
| Harout Semerjian | Director, Chief Executive Officer | 21 Jan 2022 | 423,500 | 423,500 | - | - | Employee Stock Option (right to buy) | ||
| Patricia S. Andrews | Director | Purchase of securities on an exchange or from another person at price $ 2.05 per share. | 16 Nov 2021 | 40,000 | 45,250 (0%) | 0% | 2.1 | 82,000 | Common Stock |
| Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 5,250 | 43,250 (0%) | 0% | 0 | Common Stock | |
| Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 10,500 | 10,500 | - | - | Stock Option (right to buy) | |
| Mark Alan Goldberg | Director | 18 May 2021 | 5,250 | 5,250 (0%) | 0% | 0 | Common Stock | ||
| Mark Alan Goldberg | Director | 18 May 2021 | 10,500 | 10,500 | - | - | Stock Option (right to buy) | ||
| Patricia S. Andrews | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 10,500 | 10,500 | - | - | Stock Option (right to buy) | |
| Patricia S. Andrews | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 5,250 | 5,250 (0%) | 0% | 0 | Common Stock | |
| Scott T. Jackson | Director | 18 May 2021 | 5,250 | 5,250 (0%) | 0% | 0 | Common Stock | ||
| Scott T. Jackson | Director | 18 May 2021 | 10,500 | 10,500 | - | - | Stock Option (right to buy) | ||
| Timothy R. Pearson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 10,500 | 10,500 | - | - | Stock Option (right to buy) | |
| Timothy R. Pearson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 5,250 | 5,250 (0%) | 0% | 0 | Common Stock | |
| Scott Koenig | Director | 18 May 2021 | 10,500 | 10,500 | - | - | Stock Option (right to buy) | ||
| Scott Koenig | Director | 18 May 2021 | 5,250 | 5,250 (0%) | 0% | 0 | Common Stock | ||
| Rachel K. King | Director, President, CEO | 20 Jan 2021 | 96,250 | 452,314 (1%) | 0% | 0 | Common Stock | ||
| Rachel K. King | Director, President, CEO | 20 Jan 2021 | 192,500 | 192,500 | - | - | Employee Stock Option (right to buy) | ||
| John L. Magnani | SVP of Research, CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2021 | 34,500 | 324,260 (0%) | 0% | 0 | Common Stock | |
| John L. Magnani | SVP of Research, CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2021 | 69,000 | 69,000 | - | - | Employee Stock Option (right to buy) | |
| Helen M. Thackray | SVP Clinical Development, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2021 | 34,500 | 183,115 (0%) | 0% | 0 | Common Stock | |
| Helen M. Thackray | SVP Clinical Development, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2021 | 69,000 | 69,000 | - | - | Employee Stock Option (right to buy) | |
| Brian M. Hahn | SVP Finance, CFO | 20 Jan 2021 | 69,000 | 69,000 | - | - | Employee Stock Option (right to buy) | ||
| Brian M. Hahn | SVP Finance, CFO | 20 Jan 2021 | 34,500 | 39,760 (0%) | 0% | 0 | Common Stock | ||
| Armand Girard | SVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2021 | 50,000 | 50,000 | - | - | Employee Stock Option (right to buy) | |
| Armand Girard | SVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2021 | 25,000 | 25,000 (0%) | 0% | 0 | Common Stock | |
| Rachel K. King | Director, President, CEO | 28 Dec 2020 | 130,821 | 440,240 (1%) | 0% | 1.1 | 146,520 | Common Stock | |
| Rachel K. King | Director, President, CEO | 28 Dec 2020 | 130,821 | 0 | - | - | Employee Stock Option (right to buy) | ||
| Rachel K. King | Director, President, CEO | 28 Dec 2020 | 84,176 | 356,064 (0%) | 0% | 3.9 | 329,128 | Common Stock | |
| Brian M. Hahn | SVP Finance, CFO | 16 Dec 2020 | 5,260 | 5,260 (0%) | 0% | 1.1 | 5,891 | Common Stock | |
| Brian M. Hahn | SVP Finance, CFO | 16 Dec 2020 | 5,260 | 0 | - | - | Employee Stock Option (right to buy) | ||
| Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2020 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Mark A. Goldberg | Director | 22 May 2020 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | ||
| Patricia S. Andrews | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2020 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Scott T. Jackson | Director | 22 May 2020 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | ||
| Timothy R. Pearson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2020 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Scott Koenig | Director | 22 May 2020 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | ||
| Daniel M. Junius | Director | Purchase of securities on an exchange or from another person at price $ 3.40 per share. | 09 Mar 2020 | 20,000 | 38,000 (0%) | 0% | 3.4 | 68,000 | Common Stock |
| Rachel K. King | Director, President, CEO | 22 Jan 2020 | 349,000 | 349,000 | - | - | Employee Stock Option (right to buy) | ||
| John L. Magnani | SVP of Research, CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2020 | 120,000 | 120,000 | - | - | Employee Stock Option (right to buy) | |
| Helen M. Thackray | SVP Clinical Development, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2020 | 120,000 | 120,000 | - | - | Employee Stock Option (right to buy) | |
| Brian M. Hahn | SVP Finance, CFO | 22 Jan 2020 | 120,000 | 120,000 | - | - | Employee Stock Option (right to buy) | ||
| Armand Girard | SVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2020 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| John L. Magnani | SVP of Research, CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2020 | 106,983 | 0 | - | - | Employee Stock Option (right to buy) | |
| John L. Magnani | SVP of Research, CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 06 Jan 2020 | 106,983 | 289,760 (0%) | 0% | 1.1 | 119,821 | Common Stock |
| John L. Magnani | SVP of Research, CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2019 | 106,984 | 106,983 | - | - | Employee Stock Option (right to buy) | |
| John L. Magnani | SVP of Research, CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 20 Dec 2019 | 106,984 | 182,777 (0%) | 0% | 1.1 | 119,822 | Common Stock |
| Daniel M. Junius | None | Purchase of securities on an exchange or from another person at price $ 3.18 per share. | 13 Aug 2019 | 10,000 | 18,000 (0%) | 0% | 3.2 | 31,800 | Common Stock |
| Rachel K. King | Director, President, CEO | 06 Aug 2019 | 166,759 | 307,144 (0%) | 0% | 1.1 | 186,770 | Common Stock | |
| Rachel K. King | Director, President, CEO | 06 Aug 2019 | 166,759 | 130,821 | - | - | Employee Stock Option (right to buy) | ||
| Daniel M. Junius | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2019 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Mark A. Goldberg | None | 17 May 2019 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | ||
| Patricia S. Andrews | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2019 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Scott T. Jackson | None | 17 May 2019 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | ||
| Timothy R. Pearson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2019 | 21,000 | 21,000 | - | - | Common Stock | |
| Scott Koenig | None | 17 May 2019 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | ||
| Rachel K. King | Director, President, CEO | 17 Jan 2019 | 265,000 | 265,000 | - | - | Employee Stock Option (right to buy) | ||
| John L. Magnani | Director, SVP of Research, CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2019 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Helen M. Thackray | SVP Clinical Development, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2019 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Brian M. Hahn | SVP Finance, CFO | 17 Jan 2019 | 90,000 | 90,000 | - | - | Employee Stock Option (right to buy) | ||
| Scott T. Jackson | None | 27 Nov 2018 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | ||
| John L. Magnani | Director, SVP of Research, CSO | Sale of securities on an exchange or to another person at price $ 14.02 per share. | 16 Oct 2018 | 3,527 | 75,793 (0%) | 0% | 14.0 | 49,449 | Common Stock |
| John L. Magnani | Director, SVP of Research, CSO | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 16 Oct 2018 | 7,273 | 79,320 (0%) | 0% | 14 | 101,822 | Common Stock |
| John L. Magnani | Director, SVP of Research, CSO | Sale of securities on an exchange or to another person at price $ 14.01 per share. | 16 Oct 2018 | 14,200 | 86,593 (0%) | 0% | 14.0 | 198,942 | Common Stock |
| Brian M. Hahn | CFO | 11 Jun 2018 | 5,260 | 19,345 (0%) | 0% | 1.1 | 5,891 | Common Stock | |
| Brian M. Hahn | CFO | 11 Jun 2018 | 5,260 | 5,260 | - | - | Employee Stock Option (right to buy) | ||
| Brian M. Hahn | CFO | 11 Jun 2018 | 19,345 | 0 (0%) | 0% | 18.0 | 348,984 | Common Stock | |
| John L. Magnani | Director, SVP of Research, CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.33 per share. | 23 May 2018 | 1,491 | 100,793 (0%) | 0% | 0.3 | 492 | Common Stock |
| John L. Magnani | Director, SVP of Research, CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2018 | 895 | 0 | - | - | Warrant to Purchase Common Stock (right to buy) | |
| John L. Magnani | Director, SVP of Research, CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2018 | 596 | 0 | - | - | Warrant to Purchase Common Stock (right to buy) | |
| Daniel M. Junius | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| M. James Barrett | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Mark A. Goldberg | None | 18 May 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | ||
| Patricia S. Andrews | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Timothy R. Pearson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Scott Koenig | None | 18 May 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | ||
| M. James Barrett | Director, Ten Percent Owner | 10 May 2018 | 298,406 | 0 | - | - | Warrant to Purchase Common Stock (right to buy) | ||
| M. James Barrett | Director, Ten Percent Owner | 10 May 2018 | 216,046 | 0 | - | - | Warrant to Purchase Common Stock (right to buy) | ||
| M. James Barrett | Director, Ten Percent Owner | 10 May 2018 | 298,406 | 5,001,197 (11%) | 0% | 0.3 | 98,474 | Common Stock | |
| M. James Barrett | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 17.81 per share. | 10 May 2018 | 4,006 | 4,702,791 (11%) | 0% | 17.8 | 71,347 | Common Stock |
| M. James Barrett | Director, Ten Percent Owner | 10 May 2018 | 216,046 | 4,706,797 (11%) | 0% | 0.3 | 71,295 | Common Stock | |
| M. James Barrett | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 17.81 per share. | 10 May 2018 | 5,533 | 4,995,664 (11%) | 0% | 17.8 | 98,543 | Common Stock |
| Peter J. Barris | Ten Percent Owner | 10 May 2018 | 298,406 | 5,001,197 (11%) | 0% | 0.3 | 98,474 | Common Stock | |
| Peter J. Barris | Ten Percent Owner | 10 May 2018 | 216,046 | 0 | - | - | Warrant to Purchase Common Stock (right to buy) | ||
| Peter J. Barris | Ten Percent Owner | 10 May 2018 | 298,406 | 0 | - | - | Warrant to Purchase Common Stock (right to buy) | ||
| Peter J. Barris | Ten Percent Owner | 10 May 2018 | 216,046 | 4,706,797 (11%) | 0% | 0.3 | 71,295 | Common Stock | |
| Peter J. Barris | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 17.81 per share. | 10 May 2018 | 4,006 | 4,702,791 (11%) | 0% | 17.8 | 71,347 | Common Stock |
| Peter J. Barris | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 17.81 per share. | 10 May 2018 | 5,533 | 4,995,664 (11%) | 0% | 17.8 | 98,543 | Common Stock |
| Sandell D Scott | Ten Percent Owner | 10 May 2018 | 216,046 | 0 | - | - | Warrant to Purchase Common Stock (right to buy) | ||
| Sandell D Scott | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 17.81 per share. | 10 May 2018 | 5,533 | 4,995,664 (11%) | 0% | 17.8 | 98,543 | Common Stock |
| Sandell D Scott | Ten Percent Owner | 10 May 2018 | 298,406 | 5,001,197 (11%) | 0% | 0.3 | 98,474 | Common Stock | |
| Sandell D Scott | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 17.81 per share. | 10 May 2018 | 4,006 | 4,702,791 (11%) | 0% | 17.8 | 71,347 | Common Stock |
| Sandell D Scott | Ten Percent Owner | 10 May 2018 | 216,046 | 4,706,797 (11%) | 0% | 0.3 | 71,295 | Common Stock | |
| Sandell D Scott | Ten Percent Owner | 10 May 2018 | 298,406 | 0 | - | - | Warrant to Purchase Common Stock (right to buy) | ||
| Rachel K. King | Director, President, CEO | 10 Jan 2018 | 175,000 | 175,000 | - | - | Employee Stock Option (right to buy) | ||
| John L. Magnani | Director, SVP of Research, CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2018 | 75,000 | 75,000 | - | - | Employee Stock Option (right to buy) | |
| Helen M. Thackray | SVP Clinical Development, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2018 | 75,000 | 75,000 | - | - | Employee Stock Option (right to buy) | |
| Brian M. Hahn | CFO | 10 Jan 2018 | 65,000 | 65,000 | - | - | Employee Stock Option (right to buy) | ||
| Rachel K. King | Director, President, CEO | 31 Dec 2017 | 23,301 | 23,301 (0%) | 0% | 0 | Common Stock | ||
| Rachel K. King | Director, President, CEO | 31 Dec 2017 | 23,301 | 23,301 (0%) | 0% | 0 | Common Stock | ||
| Rachel K. King | Director, President, CEO | 31 Dec 2017 | 46,602 | 0 (0%) | 0% | 0 | Common Stock | ||
| Helen M. Thackray | SVP Clinical Development, CMO | Sale of securities on an exchange or to another person at price $ 15.01 per share. | 08 Dec 2017 | 2,000 | 148,615 (0%) | 0% | 15.0 | 30,020 | Common Stock |
| Helen M. Thackray | SVP Clinical Development, CMO | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 18 Sep 2017 | 2,000 | 150,615 (0%) | 0% | 13 | 26,000 | Common Stock |
| Daniel M. Junius | None | Grant, award, or other acquisition of securities at price $ 11.27 per share. | 15 Jun 2017 | 3,000 | 8,000 (0%) | 0% | 11.3 | 33,810 | Common Stock |
| Patricia S. Andrews | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2017 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Daniel M. Junius | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2017 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| M. James Barrett | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2017 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Mark A. Goldberg | None | 25 May 2017 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | ||
| Timothy R. Pearson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2017 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Scott Koenig | None | 25 May 2017 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | ||
| Helen M. Thackray | SVP Clinical Development, CMO | Sale of securities on an exchange or to another person at price $ 15.57 per share. | 25 May 2017 | 2,000 | 152,615 (0%) | 0% | 15.6 | 31,140 | Common Stock |
| Helen M. Thackray | SVP Clinical Development, CMO | Sale of securities on an exchange or to another person at price $ 12.14 per share. | 19 May 2017 | 2,000 | 154,615 (0%) | 0% | 12.1 | 24,280 | Common Stock |
| John L. Magnani | Director, SVP of Research, CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 10 May 2017 | 8,928 | 99,302 (0%) | 0% | 1.1 | 9,999 | Common Stock |
| John L. Magnani | Director, SVP of Research, CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2017 | 8,928 | 213,967 | - | - | Employee Stock Option (right to buy) | |
| Scott Koenig | None | 09 Mar 2017 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | ||
| Rachel K. King | Director, President, CEO | 04 Jan 2017 | 175,000 | 175,000 | - | - | Employee Stock Option (right to buy) | ||
| John L. Magnani | Director, SVP of Research, CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2017 | 75,000 | 75,000 | - | - | Employee Stock Option (right to buy) | |
| Helen M. Thackray | SVP Clinical Development, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2017 | 75,000 | 75,000 | - | - | Employee Stock Option (right to buy) | |
| Brian M. Hahn | CFO | 04 Jan 2017 | 65,000 | 65,000 | - | - | Employee Stock Option (right to buy) | ||
| Daniel M. Junius | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 20 Dec 2016 | 5,000 | 5,000 | - | - | Common Stock | |
| Helen M. Thackray | VP Clinical Development, CMO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 03 Oct 2016 | 3,900 | 156,715 | - | - | Common Stock | |
| Helen M. Thackray | VP Clinical Development, CMO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 03 Oct 2016 | 100 | 156,615 | - | - | Common Stock | |
| Helen M. Thackray | VP Clinical Development, CMO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 20 Jul 2016 | 2,000 | 160,615 | - | - | Common Stock | |
| Helen M. Thackray | VP Clinical Development, CMO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 01 Jul 2016 | 6,796 | 162,615 | - | - | Common Stock | |
| Helen M. Thackray | VP Clinical Development, CMO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 01 Jul 2016 | 10,136 | 169,411 | - | - | Common Stock | |
| Helen M. Thackray | VP Clinical Development, CMO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 01 Jul 2016 | 5,068 | 179,547 | - | - | Common Stock | |
| John Baldwin | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2016 | 605 | 1,210 | - | - | Common Stock | |
| John Baldwin | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2016 | 605 | 0 | - | - | Stock Option (right to buy) | |
| Franklin H. Top | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2016 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| M. James Barrett | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2016 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| John Baldwin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2016 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Mark A. Goldberg | None | 17 May 2016 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | ||
| Daniel M. Junius | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2016 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Timothy R. Pearson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2016 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Daniel M. Junius | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2016 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Mark A. Goldberg | None | 04 Mar 2016 | 10,397 | 11,497 | - | - | Common Stock | ||
| Franklin H. Top | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2016 | 11,689 | 12,294 | - | - | Common Stock | |
| Franklin H. Top | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2016 | 11,084 | 0 | - | - | Stock Option (right to buy) | |
| Franklin H. Top | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2016 | 605 | 0 | - | - | Stock Option (right to buy) | |
| Rachel K. King | Director, President, CEO | 07 Jan 2016 | 141,000 | 141,000 | - | - | Employee Stock Option (right to buy) | ||
| John L. Magnani | Director, VP of Research, CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2016 | 71,000 | 71,000 | - | - | Employee Stock Option (right to buy) | |
| Helen M. Thackray | VP Clinical Development, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2016 | 71,000 | 71,000 | - | - | Employee Stock Option (right to buy) | |
| Brian M. Hahn | CFO | 07 Jan 2016 | 65,000 | 65,000 | - | - | Employee Stock Option (right to buy) | ||
| M. James Barrett | Director, Ten Percent Owner | 16 Nov 2015 | 9,445 | 0 | - | - | Warrant to Purchase Common Stock (right to buy) | ||
| M. James Barrett | Director, Ten Percent Owner | 16 Nov 2015 | 9,445 | 4,491,203 | - | - | Common Stock | ||
| M. James Barrett | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 16 Nov 2015 | 452 | 4,490,751 | - | - | Common Stock | |
| Peter J. Barris | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 16 Nov 2015 | 452 | 4,490,751 | - | - | Common Stock | |
| Peter J. Barris | Ten Percent Owner | 16 Nov 2015 | 9,445 | 4,491,203 | - | - | Common Stock | ||
| Peter J. Barris | Ten Percent Owner | 16 Nov 2015 | 9,445 | 0 | - | - | Warrant to Purchase Common Stock (right to buy) | ||
| Sandell D Scott | Ten Percent Owner | 16 Nov 2015 | 9,445 | 0 | - | - | Warrant to Purchase Common Stock (right to buy) | ||
| Sandell D Scott | Ten Percent Owner | 16 Nov 2015 | 9,445 | 4,491,203 | - | - | Common Stock | ||
| Sandell D Scott | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 16 Nov 2015 | 452 | 4,490,751 | - | - | Common Stock | |
| Michael A. Henos | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2015 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Franklin H. Top | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2015 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| M. James Barrett | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2015 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| John Baldwin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2015 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Mark A. Goldberg | None | 15 Jul 2015 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | ||
| Timothy R. Pearson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2015 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Brian M. Hahn | CFO | 27 Feb 2015 | 5,000 | 14,085 | - | - | Common Stock | ||
| Brian M. Hahn | CFO | 27 Feb 2015 | 5,000 | 10,520 | - | - | Employee Stock Option (right to buy) | ||
| Rachel K. King | Director, President, CEO | 24 Feb 2015 | 50,000 | 167,206 | - | - | Common Stock | ||
| Rachel K. King | Director, President, CEO | 24 Feb 2015 | 50,000 | 297,580 | - | - | Employee Stock Option (right to buy) | ||
| Rachel K. King | Director, President, CEO | 08 Jan 2015 | 141,000 | 141,000 | - | - | Employee Stock Option (right to buy) | ||
| John L. Magnani | Director, VP of Research, CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2015 | 71,000 | 71,000 | - | - | Employee Stock Option (right to buy) | |
| Helen M. Thackray | VP Clinical Development, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2015 | 71,000 | 71,000 | - | - | Employee Stock Option (right to buy) | |
| Brian M. Hahn | CFO | 08 Jan 2015 | 61,000 | 61,000 | - | - | Employee Stock Option (right to buy) | ||
| Michael A. Henos | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 19 Dec 2014 | 10,659 | 469,454 | - | - | Common Stock | |
| Michael A. Henos | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 19 Dec 2014 | 10,598 | 480,113 | - | - | Common Stock | |
| Michael A. Henos | None | 15 Dec 2014 | 5,133 | 0 | - | - | Warrant to Purchase Common Stock (right to buy) | ||
| Michael A. Henos | None | 15 Dec 2014 | 38,493 | 0 | - | - | Warrant to Purchase Common Stock (right to buy) | ||
| Michael A. Henos | None | 15 Dec 2014 | 43,628 | 497,436 | - | - | Common Stock | ||
| Michael A. Henos | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 15 Dec 2014 | 5,121 | 490,711 | - | - | Common Stock | |
| Michael A. Henos | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 15 Dec 2014 | 1,604 | 495,832 | - | - | Common Stock | |
| Mark A. Goldberg | None | 08 Jul 2014 | 15,401 | 15,401 | - | - | Stock Option (right to buy) | ||
| Rachel K. King | Director, President, CEO | 18 Jun 2014 | 100,000 | 108,706 | - | - | Common Stock | ||
| Rachel K. King | Director, President, CEO | 18 Jun 2014 | 100,000 | 347,580 | - | - | Employee Stock Option (right to buy) | ||
| Michael A. Henos | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 12 Jun 2014 | 6,000 | 7,562 | - | - | Common Stock | |
| Michael A. Henos | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 12 Jun 2014 | 5,000 | 12,562 | - | - | Common Stock | |
| Michael A. Henos | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2014 | 1,562 | 1,562 | - | - | Common Stock | |
| Michael A. Henos | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2014 | 1,562 | 0 | - | - | Stock Option (right to buy) | |
| Timothy R. Pearson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2014 | 15,401 | 15,401 | - | - | Stock Option (right to buy) | |
| David M. Mott | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 15 Jan 2014 | 512,500 | 4,093,377 | - | - | Common Stock | |
| David M. Mott | Ten Percent Owner | 15 Jan 2014 | 11,824,058 | 0 | - | - | Series A-1 Preferred Stock | ||
| David M. Mott | Ten Percent Owner | 15 Jan 2014 | 3,580,877 | 3,580,877 | - | - | Common Stock | ||
| Michael A. Henos | None | 15 Jan 2014 | 1,114,690 | 0 | - | - | Series A-1 Preferred Stock | ||
| Michael A. Henos | None | 15 Jan 2014 | 39,413 | 0 | - | - | Series A-1 Preferred Stock | ||
| Michael A. Henos | None | 15 Jan 2014 | 337,579 | 453,808 | - | - | Common Stock | ||
| Michael A. Henos | None | 15 Jan 2014 | 11,936 | 22,668 | - | - | Common Stock | ||
| M. James Barrett | Director, Ten Percent Owner | 15 Jan 2014 | 11,824,058 | 0 | - | - | Series A-1 Preferred Stock | ||
| M. James Barrett | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 15 Jan 2014 | 487,500 | 4,481,758 | - | - | Common Stock | |
| M. James Barrett | Director, Ten Percent Owner | 15 Jan 2014 | 3,407,283 | 3,994,258 | - | - | Common Stock | ||
| M. James Barrett | Director, Ten Percent Owner | 15 Jan 2014 | 11,250,850 | 0 | - | - | Series A-1 Preferred Stock | ||
| M. James Barrett | Director, Ten Percent Owner | 15 Jan 2014 | 3,580,877 | 3,580,877 | - | - | Common Stock | ||
| M. James Barrett | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 15 Jan 2014 | 512,500 | 4,093,377 | - | - | Common Stock | |
| Peter J. Barris | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 15 Jan 2014 | 487,500 | 4,481,758 | - | - | Common Stock | |
| Peter J. Barris | Ten Percent Owner | 15 Jan 2014 | 3,580,877 | 3,580,877 | - | - | Common Stock | ||
| Peter J. Barris | Ten Percent Owner | 15 Jan 2014 | 11,250,850 | 0 | - | - | Series A-1 Preferred Stock | ||
| Peter J. Barris | Ten Percent Owner | 15 Jan 2014 | 11,824,058 | 0 | - | - | Series A-1 Preferred Stock | ||
| Peter J. Barris | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 15 Jan 2014 | 512,500 | 4,093,377 | - | - | Common Stock | |
| Peter J. Barris | Ten Percent Owner | 15 Jan 2014 | 3,407,283 | 3,994,258 | - | - | Common Stock | ||
| Sandell D Scott | Ten Percent Owner | 15 Jan 2014 | 3,580,877 | 3,580,877 | - | - | Common Stock | ||
| Sandell D Scott | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 15 Jan 2014 | 487,500 | 4,481,758 | - | - | Common Stock | |
| Sandell D Scott | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 15 Jan 2014 | 512,500 | 4,093,377 | - | - | Common Stock | |
| Sandell D Scott | Ten Percent Owner | 15 Jan 2014 | 3,407,283 | 3,994,258 | - | - | Common Stock | ||
| Sandell D Scott | Ten Percent Owner | 15 Jan 2014 | 11,824,058 | 0 | - | - | Series A-1 Preferred Stock | ||
| Sandell D Scott | Ten Percent Owner | 15 Jan 2014 | 11,250,850 | 0 | - | - | Series A-1 Preferred Stock | ||
| John L. Magnani | Director, VP of Research, CSO | 15 Jan 2014 | 32,918 | 0 | - | - | Series A-1 Preferred Stock | ||
| John L. Magnani | Director, VP of Research, CSO | 15 Jan 2014 | 9,969 | 90,374 | - | - | Common Stock | ||
| William M. Gust | None | 15 Jan 2014 | 339,686 | 409,947 | - | - | Common Stock | ||
| William M. Gust | None | 15 Jan 2014 | 1,121,646 | 0 | - | - | Series A-1 Preferred Stock | ||
| Michael A. Henos | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2014 | 15,401 | 15,401 | - | - | Stock Option (right to buy) | |
| Franklin H. Top | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2014 | 15,401 | 15,401 | - | - | Stock Option (right to buy) | |
| M. James Barrett | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2014 | 15,401 | 15,401 | - | - | Stock Option (right to buy) | |
| John Baldwin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2014 | 15,401 | 15,401 | - | - | Stock Option (right to buy) | |
| Rachel K. King | Director, President, CEO | 09 Jan 2014 | 375,639 | 375,639 | - | - | Stock Option (right to buy) | ||
| John L. Magnani | Director, VP of Research, CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2014 | 169,038 | 169,038 | - | - | Stock Option (right to buy) | |
| Helen M. Thackray | VP Clinical Development, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2014 | 112,692 | 112,692 | - | - | Stock Option (right to buy) | |
| Brian M. Hahn | CFO | 09 Jan 2014 | 37,564 | 37,564 | - | - | Stock Option (right to buy) | ||
| William M. Gust | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2014 | 15,401 | 15,401 | - | - | Stock Option (right to buy) |